Active ingredientImegliminCat. No. P-I027-001CAS 775351-65-0Family · Pharmaceutical analytical standards
Imeglimin
An oral medicine for type 2 diabetes, the first approved of a new class: it acts on mitochondria, reduces glucose output by the liver and improves insulin secretion. It was approved in Japan in June 2021. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Its molecule is built around a tetrahydrotriazine ring, a cyclic structure related to the biguanides, the family of metformin, but it acts differently on the mitochondrial respiratory chain.
Go to the active ingredient →Active ingredientImegliminCat. No. P-I027-001CAS 775351-65-0
Active ingredientImeglimin HClCat. No. P-I027-002CAS 775351-61-6
Isotopically labelledImeglimin-d6Cat. No. P-I027-003
NitrosamineN-Nitroso ImegliminCat. No. P-I027-004
ImpurityImeglimin Impurity 1Cat. No. P-I027-005CAS 21320-31-0
Impurityrac-ImegliminCat. No. P-I027-006CAS 757178-57-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.